优化12β-O-γ-Glutamyl Oleanolic 酸衍生物的结构,从而产生用于NASH治疗的强大的FXR对手/调节器
Hao Ma1, Yunyang Bao2, Shuaishuai Niu1
1State Key Laboratory of Bioactive Substances and Functions of Natural Medicines & Ministry of Health Key Laboratory of Biosynthesis of Natural Products, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 2A Nan Wei Road, Beijing 100050, China.
一种新型的烯酸衍生物,化合物10b,选择性地对抗法尔内索伊德X受体 (FXR). 这种化合物通过减少肝脂积累和纤维化来治疗非酒精性脂肪肝炎 (NASH) 是有前途的.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 药用化学 医学化学
背景情况:
- 方氏体X受体 (FXR) 是胆酸,脂质和葡萄糖代谢的关键调节器,使其成为代谢疾病的治疗点.
- FXR功能障碍与胆固醇,糖尿病,高脂血症和癌症有关,这凸显了对新型FXR调节器的需求.
研究的目的:
- 设计和合成具有潜在FXR调节活性的新型烯酸 (OA) 衍生物.
- 在肝病的临床前模型中评估这些衍生物的疗效.
主要方法:
- 合成具有12β-O-(γ-glutamyl) 基的烯酸衍生物.
- 酵母单杂交试验用于初步结构-活性关系 (SAR) 分析.
- 在体内对BDL大鼠和HFD小鼠进行研究,以评估肝脏健康和纤维化.
主要成果:
- 化合物10b被确定为一种强效和选择性的FXR抗剂.
- 化合物10b上调了CYP7A1基因,并在体内显著抑制了肝脂积累和纤维化.
- 分子建模表明,在FXR联体结合域内,10b具有独特的结合相互作用.
结论:
- 12 - 氨基酸衍生物10b对非酒精性脂肪肝炎 (NASH) 显示出有前途的治疗潜力.
- 化合物10b的独特机制,包括CYP7A1上调,使其与现有的OA衍生品有所区别.
更多相关视频
09:09Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
Published on: September 20, 2016
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Drug Metabolism: Phase II Reactions
Drug Biotransformation: Overview
